Melphalan 50mg Vial with Solvent

Melphalan Injection is for intravenous use and regional arterial perfusion only. Melphalan Injection should not be given without haematopoietic stem cell rescue at doses of above 140 mg/m².

For intravenous administration, it is recommended that Melphalan Injection solution is injected slowly into a fast-running infusion solution via a swabbed injection port.

If direct injection into a fast-running infusion is not appropriate, Melphalan Injection solution may be administered diluted in an infusion bag.

Melphalan is not compatible with infusion solutions containing dextrose and it is recommended that only sodium chloride intravenous infusion 0.9% w/v is used.

Very common: More than 1 in 10 people who have Melphalan hydrochloride:

• abnormal laboratory test results
• blood and bone marrow problem
• feelings of warmth
• muscle fibrosis
• muscle pain or tenderness
• muscle wasting
• nausea
• side effects that may occur if Melphalan hydrochloride is taken at a high dose. These may include hair loss or inflammation of the mouth
• tingling
• vomiting

Common: More than 1 in 100 people who have Melphalan hydrochloride:

• compartment syndrome

Rare: More than 1 in 10,000 people who have Melphalan hydrochloride:

• allergic reactions including rashes, urticaria, oedema, anaphylactic shock or cardiac arrest
• itching
• jaundice
• liver problems
• lung problems – some lung problems may be fatal